MiniMed Group, Inc.

424B4 priced

MiniMed Group, Inc. is conducting an initial public offering (IPO) of 28,000,000 shares of common stock at $20.00 per share, with proceeds totaling $560 million. The offering follows a separation from its parent company, Medtronic, which will retain 90.03% of voting shares post-offering, maintaining MiniMed as a 'controlled company' under Nasdaq rules. The filing outlines agreements related to the separation, including asset transfers, tax matters, employee arrangements, and a potential future tax-free divestment of Medtronic's remaining stake.

8-A12B effective

MiniMed Group, Inc. is registering its common stock under Section 12(b) of the Securities Exchange Act of 1934 via Form 8-A12B, referencing its prior S-1/A filing for the initial public offering (IPO). The registration incorporates by reference the common stock description from the S-1/A, which outlines the IPO details, including the separation from Medtronic and the proposed listing on Nasdaq. No new material details are provided in the current filing beyond the registration process.

EFFECT effective

MiniMed Group, Inc. has received effectiveness for its S-1 registration statement, marking the formal initiation of its IPO process. The filing registers common stock for trading on Nasdaq, following an earlier 8-A12B submission that outlined similar securities registration. The current notice confirms the company's readiness to proceed with public offering under the Securities Exchange Act of 1934.

S-1/A amended

MiniMed Group, Inc. is conducting an initial public offering (IPO) of 28,000,000 shares of common stock, with an estimated price range of $25.00 to $28.00 per share. The offering follows a separation from its parent company, Medtronic, which will retain 90.03% of voting power post-offering, making MiniMed a 'controlled company' under Nasdaq rules. The filing details the Separation transactions, including asset transfers, tax agreements, and a planned Divestment where Medtronic intends to distribute its remaining equity in MiniMed to shareholders, subject to regulatory and market conditions.

S-1/A amended

MiniMed Group, Inc. is conducting an initial public offering (IPO) of 28,000,000 shares of common stock, with an estimated price range of $25.00 to $28.00 per share. The offering follows a separation from its parent company, Medtronic, which will retain 90.03% of voting power post-offering, making MiniMed a 'controlled company' under Nasdaq rules. The filing details the separation process, including asset transfers, tax agreements, and a potential future divestment of Medtronic's remaining stake. The company plans to list on Nasdaq under the symbol 'MMED'.

S-1/A amended

MiniMed Group, Inc. is conducting an initial public offering (IPO) of its common stock, with the proceeds intended to fund its separation from parent company Medtronic. The offering will result in Medtronic retaining a significant ownership stake, but a subsequent divestment plan aims to distribute its remaining equity to shareholders through a tax-free spin-off or similar structure. The filing outlines complex transaction agreements, including asset transfers, tax matters, and transition services, to facilitate the separation.

S-1 filed

MiniMed Group, Inc. is conducting an initial public offering (IPO) of its common stock, transitioning from being a subsidiary of Medtronic to an independent entity. The offering follows a planned separation from Medtronic, involving the transfer of the Diabetes Operating Unit's assets and liabilities. Post-IPO, Medtronic will retain significant voting control, but a subsequent tax-free divestment (spin-off or split-off) is anticipated, potentially altering corporate governance requirements. The filing outlines key agreements with Medtronic, including tax, employee, and intellectual property arrangements, alongside underwriting details and risk disclosures.

DRS/A amended

MiniMed Group, Inc. is conducting an initial public offering (IPO) of its common stock, with Medtronic retaining a significant controlling stake post-offering. The filing outlines the separation of MiniMed's Diabetes Operating Unit from Medtronic, involving complex agreements to transfer assets and liabilities. A potential tax-free distribution to Medtronic shareholders is also referenced, contingent on regulatory and market conditions.

DRS/A amended

MiniMed Group, Inc. is conducting an initial public offering (IPO) of its common stock, transitioning from being a subsidiary of Medtronic. The filing outlines the separation of its Diabetes Operating Unit from Medtronic, including agreements for asset/liability transfers, tax matters, employee arrangements, and intellectual property. The IPO will be followed by a potential tax-free distribution of shares to Medtronic's shareholders, though conditions and timing remain uncertain. The company expects to become a standalone entity with Medtronic retaining significant voting control post-IPO.

DRS filed

MDT Sub Holdings, Inc. (MiniMed Group, Inc.) is conducting an initial public offering (IPO) of its common stock, following a planned separation from its parent company, Medtronic. The offering involves transferring the Diabetes Operating Unit to MDT Sub Holdings through a series of agreements, including a Separation Agreement, Tax Matters Agreement, and others. Medtronic will retain significant ownership post-offering, and a subsequent tax-free distribution to Medtronic shareholders is contemplated. The IPO is underwritten by Goldman Sachs and BofA Securities, with shares expected to be listed on [exchange]. The filing highlights risks related to the separation, distribution conditions, and governance changes.